Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Next Previous
Trial Profile

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sapanisertib (Primary) ; Serabelisib (Primary) ; Everolimus
  • Indications Carcinoma; Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology

Most Recent Events

  • 09 Dec 2022 Results assessing the efficacy and safety of single-agent sapanisertib and sapanisertib plus TAK-117, vs. everolimus in patients with advanced clear cell renal cell carcinoma , published in the Oncologist
  • 04 Jun 2020 Status changed from active, no longer recruiting to completed.
  • 24 May 2020 This trial has been completed in Poland, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top